Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma

被引：19
|
作者：
Chan, Kah-Lok [1 ]
Filshie, Robin [1 ]
Nandurkar, Harshal [1 ]
Quach, Hang [1 ]
机构：
[1] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 07期
关键词：
HEMOLYTIC-UREMIC SYNDROME; PATIENT;
D O I：
10.3109/10428194.2014.977887
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2185 / 2186
页数：2
相关论文
共 50 条
  • [21] ANAPLASTIC MULTIPLE MYELOMA WITH COMPLETE RESPONSE TO BORTEZOMIB-BASED TRIPLET REGIMEN
    Ellithi, Moataz
    Abdullah, Hafez Mohammad
    Omar, Mohamed
    ANTICANCER RESEARCH, 2019, 39 (10) : 5848 - 5849
  • [22] BORTEZOMIB-BASED REGIMENS AS INDUCTION AND MAINTENANCE TREATMENT IN MULTIPLE MYELOMA (MM) PATIENTS NOT ELIGIBLE FOR AGGRESSIVE THERAPY
    Mazzone, C.
    Gentile, M.
    Vigna, E.
    Lucia, E.
    Lorio, C.
    Morelli, R.
    Bisconte, M. G.
    Gentile, C.
    Morabito, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 544 - 544
  • [23] Bortezomib-Based Triplet Therapy As First Line Treatment in Newly Diagnosed Multiple Myeloma Patients in Peru
    Vasquez, Jule F.
    Cordova, Naty Lopez
    Castillo, Claudia
    Saavedra, Alexandra
    Calle, Cindy
    Chavez, Lourdes Isabel Lopez
    Alcarraz, Cindy Elizabeth
    Rios, Pedro Eduardo Lovato
    Matuk, Alexandra La Torre
    Laboriano, Jorge
    Vilcarano, Abner
    Tokumura, Carmen
    Quintana, Shirley
    Samanez-Figari, Cesar
    Vidaurre, Tatiana
    BLOOD, 2024, 144 : 6997 - 6998
  • [24] Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma
    Li, Yang
    Yin, Ping
    Liu, Yang
    Hao, Chuanxi
    Chen, Lei
    Sun, Chao
    Wang, Sicong
    Hong, Nan
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [25] Bortezomib-Based Consolidation/Maintenance Therapy for Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
    Zhang, Shijia
    Wang, Yucai
    Datta, Yvonne
    Bachanova, Veronika
    Cooley, Sarah
    BLOOD, 2018, 132
  • [26] The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
    Robak, Pawel
    Drozdz, Izabela
    Jarych, Dariusz
    Mikulski, Damian
    Weglowska, Edyta
    Siemieniuk-Rys, Monika
    Misiewicz, Malgorzata
    Stawiski, Konrad
    Fendler, Wojciech
    Szemraj, Janusz
    Smolewski, Piotr
    Robak, Tadeusz
    CANCERS, 2020, 12 (09) : 1 - 18
  • [27] Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Yang, Deok-Hwan
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 389 - 394
  • [28] The first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma
    Ho, C-L.
    Chen, J-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib
    Alagappan, Arti
    Shah, Rupin A.
    Thomas, Sheeba K.
    Weber, Donna M.
    Wang, Michael
    Alexanian, Raymond
    Orlowski, Robert Z.
    Shah, Jatin J.
    BLOOD, 2013, 122 (21)
  • [30] The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy
    Kwon, Jihyun
    Lee, Yong-Pyo
    Park, Hee Sue
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S101 - S101
12345